Oncotelic Initiates Phase II Trial Evaluating OT-101 in Combination with KEYTRUDA^® for Mesothelioma

Oncotelic Therapeutics, Inc. announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase II Trial for OT-101, the company’s TGF-β inhibitor, in combination with Anti-PD-1 as a treatment for patients with malignant pleural mesothelioma.